RFXANK

Revision as of 14:15, 6 September 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Regulatory factor X-associated ankyrin-containing protein
Identifiers
Symbols RFXANK ; ANKRA1; BLS; F14150_1; MGC138628; RFX-B
External IDs Template:OMIM5 Template:MGI HomoloGene2760
RNA expression pattern
File:PBB GE RFXANK 202758 s at tn.png
More reference expression data
Orthologs
Template:GNF Ortholog box
Species Human Mouse
Entrez n/a n/a
Ensembl n/a n/a
UniProt n/a n/a
RefSeq (mRNA) n/a n/a
RefSeq (protein) n/a n/a
Location (UCSC) n/a n/a
PubMed search n/a n/a

Regulatory factor X-associated ankyrin-containing protein, also known as RFXANK, is a human gene.[1]

Major histocompatibility (MHC) class II molecules are transmembrane proteins that have a central role in development and control of the immune system. The protein encoded by this gene, along with regulatory factor X-associated protein and regulatory factor-5, forms a complex that binds to the X box motif of certain MHC class II gene promoters and activates their transcription. Once bound to the promoter, this complex associates with the non-DNA-binding factor MHC class II transactivator, which controls the cell type specificity and inducibility of MHC class II gene expression. This protein contains ankyrin repeats involved in protein-protein interactions. Mutations in this gene have been linked to bare lymphocyte syndrome type II, complementation group B. Two transcript variants encoding different isoforms have been described for this gene, with only one isoform showing activation activity.[1]

References

  1. 1.0 1.1 "Entrez Gene: RFXANK regulatory factor X-associated ankyrin-containing protein".

Further reading

  • Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. PMID 8889548.
  • Masternak K, Barras E, Zufferey M; et al. (1998). "A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients". Nat. Genet. 20 (3): 273–7. doi:10.1038/3081. PMID 9806546.
  • Nagarajan UM, Louis-Plence P, DeSandro A; et al. (1999). "RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency". Immunity. 10 (2): 153–62. PMID 10072068.
  • Lin JH, Makris A, McMahon C; et al. (1999). "The ankyrin repeat-containing adaptor protein Tvl-1 is a novel substrate and regulator of Raf-1". J. Biol. Chem. 274 (21): 14706–15. PMID 10329666.
  • Nagarajan UM, Peijnenburg A, Gobin SJ; et al. (2000). "Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells". J. Immunol. 164 (7): 3666–74. PMID 10725724.
  • Wiszniewski W, Fondaneche MC, Lambert N; et al. (2000). "Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B.". Immunogenetics. 51 (4–5): 261–7. PMID 10803838.
  • Nekrep N, Jabrane-Ferrat N, Peterlin BM (2000). "Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex". Mol. Cell. Biol. 20 (12): 4455–61. PMID 10825209.
  • Zhang QH, Ye M, Wu XY; et al. (2001). "Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells". Genome Res. 10 (10): 1546–60. PMID 11042152.
  • Nekrep N, Geyer M, Jabrane-Ferrat N, Peterlin BM (2001). "Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome". Mol. Cell. Biol. 21 (16): 5566–76. doi:10.1128/MCB.21.16.5566-5576.2001. PMID 11463838.
  • Dimberg J, Hugander A, Häll-Karlsson BM, Sirsjö A (2002). "RFX-B, a MHC class II transcription factor, suppressed in human colorectal adenocarcinomas". Int. J. Mol. Med. 9 (3): 213–6. PMID 11836625.
  • Strausberg RL, Feingold EA, Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.
  • Wiszniewski W, Fondaneche MC, Louise-Plence P; et al. (2003). "Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II". Immunogenetics. 54 (11): 747–55. doi:10.1007/s00251-002-0521-1. PMID 12618906.
  • Grimwood J, Gordon LA, Olsen A; et al. (2004). "The DNA sequence and biology of human chromosome 19". Nature. 428 (6982): 529–35. doi:10.1038/nature02399. PMID 15057824.
  • Wang AH, Grégoire S, Zika E; et al. (2005). "Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases". J. Biol. Chem. 280 (32): 29117–27. doi:10.1074/jbc.M500295200. PMID 15964851.
  • Krawczyk M, Masternak K, Zufferey M; et al. (2005). "New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study". Mol. Cell. Biol. 25 (19): 8607–18. doi:10.1128/MCB.25.19.8607-8618.2005. PMID 16166641.
  • Ewing RM, Chu P, Elisma F; et al. (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Mol. Syst. Biol. 3: 89. doi:10.1038/msb4100134. PMID 17353931.

Template:WikiDoc Sources